BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

413 related articles for article (PubMed ID: 33758607)

  • 1. Updates of Pathogenesis, Diagnostic and Therapeutic Perspectives for Ovarian Clear Cell Carcinoma.
    Zhu C; Xu Z; Zhang T; Qian L; Xiao W; Wei H; Jin T; Zhou Y
    J Cancer; 2021; 12(8):2295-2316. PubMed ID: 33758607
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical characteristics and prognosis of ovarian clear cell carcinoma: a 10-year retrospective study.
    Zhu C; Zhu J; Qian L; Liu H; Shen Z; Wu D; Zhao W; Xiao W; Zhou Y
    BMC Cancer; 2021 Mar; 21(1):322. PubMed ID: 33766002
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical perspectives of rare ovarian tumors: clear cell ovarian cancer.
    Fujiwara S
    Jpn J Clin Oncol; 2023 Jul; 53(8):664-672. PubMed ID: 37288485
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ovarian clear cell carcinoma with or without endometriosis origin in a single institution cohort.
    Sun M; Jiang W
    Discov Oncol; 2023 Apr; 14(1):39. PubMed ID: 37004660
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment for ovarian clear cell carcinoma with combined inhibition of WEE1 and ATR.
    Chien W; Tyner JW; Gery S; Zheng Y; Li LY; Gopinatha Pillai MS; Nam C; Bhowmick NA; Lin DC; Koeffler HP
    J Ovarian Res; 2023 Apr; 16(1):80. PubMed ID: 37087441
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression and significance of ARID1A mRNA in endometriosis- associated ovarian cancer.
    Wang Q; Wang L; L Y; Ding X; Liu A
    J BUON; 2017; 22(5):1314-1321. PubMed ID: 29135119
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Current and future strategies for treatment of ovarian clear cell carcinoma.
    Ogasawara A; Sato S; Hasegawa K
    J Obstet Gynaecol Res; 2020 Sep; 46(9):1678-1689. PubMed ID: 32578333
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Is the presence of endometriosis associated with a survival benefit in pure ovarian clear cell carcinoma?
    Sahin H; Sari ME; Cuylan ZF; Haberal AN; Sirvan L; Coban G; Yalcin I; Güngör T; Celik H; Meydanli MM; Ayhan A
    Arch Gynecol Obstet; 2018 Apr; 297(4):1005-1013. PubMed ID: 29383437
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment issues in clear cell carcinoma of the ovary: a different entity?
    Pectasides D; Pectasides E; Psyrri A; Economopoulos T
    Oncologist; 2006; 11(10):1089-94. PubMed ID: 17110628
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rethinking of treatment strategies and clinical management in ovarian clear cell carcinoma.
    Takahashi K; Takenaka M; Kawabata A; Yanaihara N; Okamoto A
    Int J Clin Oncol; 2020 Mar; 25(3):425-431. PubMed ID: 31989349
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genomics to immunotherapy of ovarian clear cell carcinoma: Unique opportunities for management.
    Oda K; Hamanishi J; Matsuo K; Hasegawa K
    Gynecol Oncol; 2018 Nov; 151(2):381-389. PubMed ID: 30217369
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Endometriosis does not confer improved prognosis in ovarian clear cell carcinoma: a retrospective study at a single institute.
    Zhao T; Shao Y; Liu Y; Wang X; Guan L; Lu Y
    J Ovarian Res; 2018 Jun; 11(1):53. PubMed ID: 29941051
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evidence for ethnic and environmental contributions to frequency of ovarian clear cell carcinoma.
    Tay SK; Cheong MA
    Aust N Z J Obstet Gynaecol; 2014 Jun; 54(3):225-30. PubMed ID: 24888594
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic impact of interleukin-6 expression in stage I ovarian clear cell carcinoma.
    Kawabata A; Yanaihara N; Nagata C; Saito M; Noguchi D; Takenaka M; Iida Y; Takano H; Yamada K; Iwamoto M; Kiyokawa T; Okamoto A
    Gynecol Oncol; 2017 Sep; 146(3):609-614. PubMed ID: 28673661
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The clinical characteristics and outcomes of cases with pure ovarian clear cell, mixed type and high-grade serous adenocarcinoma.
    Kucukgoz Gulec U; Paydas S; Guzel AB; Vardar MA; Khatib G; Gumurdulu D
    Arch Gynecol Obstet; 2015 Oct; 292(4):923-9. PubMed ID: 25855053
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic determinants in patients with uterine and ovarian clear carcinoma.
    Rauh-Hain JA; Winograd D; Growdon WB; Schorge JO; Goodman AK; Boruta DM; Berkowitz RS; Horowitz NS; Del Carmen MG
    Gynecol Oncol; 2012 May; 125(2):376-80. PubMed ID: 22366593
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Venous thromboembolism, interleukin-6 and survival outcomes in patients with advanced ovarian clear cell carcinoma.
    Matsuo K; Hasegawa K; Yoshino K; Murakami R; Hisamatsu T; Stone RL; Previs RA; Hansen JM; Ikeda Y; Miyara A; Hiramatsu K; Enomoto T; Fujiwara K; Matsumura N; Konishi I; Roman LD; Gabra H; Fotopoulou C; Sood AK
    Eur J Cancer; 2015 Sep; 51(14):1978-88. PubMed ID: 26238017
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Analysis of gene expression signatures identifies prognostic and functionally distinct ovarian clear cell carcinoma subtypes.
    Tan TZ; Ye J; Yee CV; Lim D; Ngoi NYL; Tan DSP; Huang RY
    EBioMedicine; 2019 Dec; 50():203-210. PubMed ID: 31761620
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tryptophan metabolism enzymes are potential targets in ovarian clear cell carcinoma.
    Zhang S; Gao Y; Wang P; Wang S; Wang Y; Li M; Wang A; Zhao K; Zhang Z; Sun J; Guo D; Liang Z
    Cancer Med; 2023 Dec; 12(24):21996-22005. PubMed ID: 38062922
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting DNA Damage Response Pathway in Ovarian Clear Cell Carcinoma.
    Wong OGW; Li J; Cheung ANY
    Front Oncol; 2021; 11():666815. PubMed ID: 34737943
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.